宫颈上皮内瘤变及其治疗对IVF/ICSI结局的影响
这项回顾性队列研究纳入2018至2020年间在三级医院经阴道镜活检诊断为CIN2/CIN3的不孕女性190例,比较治疗组与期待组及不同治疗亚组的IVF/ICSI结局。结果显示各组妊娠结局无差异,手术治疗组活产率略高于期待组但无统计学意义。
要点
- 治疗组与期待组的获卵数、受精率、优质胚胎率及妊娠结局均无显著差异。
- 手术治疗组从确诊病变到启动促性腺激素的时间显著长于消融组和期待组。
- CIN2/CIN3的治疗不影响IVF/ICSI结局,CIN2患者可入组IVF/ICSI并密切随访。
核心结论
- 对于CIN2/CIN3患者,宫颈病变治疗不影响IVF/ICSI结局。
- CIN2患者可入组IVF/ICSI周期并密切随访以防止宫颈病变进展,避免进一步延迟启动辅助生殖技术。
- CIN3患者可在宫颈病变治疗后尽快开始促排卵和胚胎冻存,9-12个月后可行冻融胚胎移植。
研究设计与样本
- 2018年至2020年间在三级医院纳入190例IVF/ICSI前HPV筛查或细胞学异常且经阴道镜活检诊断为CIN2/CIN3的不孕女性,进行回顾性队列研究,随访至2021年12月31日。
- 患者分为治疗组和期待管理组,治疗组再分为消融治疗组和手术治疗组。
主要发现
- 190例患者中152例诊断为CIN2,38例为CIN3;治疗组与期待组基线数据无显著差异。
- 手术治疗组从确诊病变到启动促性腺激素的时间显著长于消融治疗组(P=0.007)和期待组(P=0.024)。
- 治疗组与期待组平均获卵数分别为12.95±8.77和13.32±9.16,受精率分别为71.01±23.86和64.84±26.24,优质胚胎率分别为48.93±30.72和55.17±34.13,均无差异,不同治疗亚组间也未检测到差异。
- 各组间HCG阳性率、临床妊娠率、流产率、活产率或累计妊娠率均无差异。
- 手术治疗组活产率略高于期待组(77.78%对66.67%),但差异无统计学意义;手术治疗组和期待组3年累计妊娠率分别为58.19%和64.00%。
临床怎么用
- 作者认为,对于CIN2/CIN3患者,宫颈病变治疗不影响IVF/ICSI结局。
- 作者认为,CIN2患者可入组IVF/ICSI周期,密切随访以防止宫颈病变进展,避免进一步延迟启动辅助生殖技术。
- 作者认为,CIN3患者可在宫颈病变治疗后尽快开始促排卵和胚胎冻存,9-12个月后可行冻融胚胎移植。
局限性
- 本研究为回顾性研究,本质上可能包含选择偏倚。
- 期待组病例数<30,样本量小可能导致假阴性结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does treatment selection for cervical lesions affect the outcome of IVF/ICSI? SUMMARY ANSWER: There was no difference in pregnancy outcome between treated and untreated groups, or between different types of IVF/ICSI treatment. WHAT IS KNOWN ALREADY: Human papillomavirus (HPV) infection and HPV-induced cervical lesions are associated with decreased fertility, and cervical intraepithelial neoplasia (CIN) treatment may increase the risk of adverse pregnancy outcomes. STUDY DESIGN, SIZE, DURATION: Between 2018 and 2020, 190 women with infertility who had abnormal HPV screening or cytology results prior to IVF/ICSI, and were diagnosed with CIN2/CIN3 by colposcopy biopsy at a tertiary hospital, were enrolled in a retrospective cohort study with follow-up until 31 December 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients with infertility who were diagnosed with CIN2/CIN3 by colposcopy biopsy were divided into the treatment and expectant management groups. The treatment group was divided into two intervention subgroups: the ablative therapy group and the surgical treatment group. The baseline data, number of oocytes retrieved, and rates of fertilization, high-quality embryos, positive serum HCG, clinical pregnancy, abortion, live birth, and cumulative pregnancy were compared among groups. MAIN RESULTS AND THE ROLE OF CHANCE: Among the 190 patients included in the study, 152 were diagnosed with CIN2, and 38 patients had CIN3. There was no significant difference in the baseline data between the treatment and expectant groups. The time from confirmed lesions to the onset of gonadotrophin administration in the surgical treatment group was significantly longer than in the ablative therapy group and the expectant group (P = 0.007 and P = 0.024, respectively). For the treatment and expectant groups, respectively, the average number of oocytes retrieved (12.95 ± 8.77; 13.32 ± 9.16), fertilization rate (71.01 ± 23.86; 64.84 ± 26.24), and high-quality embryo rate (48.93 ± 30.72; 55.17 ± 34.13) did not differ, and no differences were detected between the different treatment subgroups. There were no differences among groups in rates of HCG positivity, clinical pregnancy, miscarriage, live birth, or cumulative pregnancy. The live birth rate in the surgical treatment group was slightly higher than that in the expectant groups (77.78% versus 66.67%), but the difference was not statistically significant. The 3-year cumulative pregnancy rates in the surgical treatment and expectant groups were 58.19% and 64.00%, respectively. LIMITATIONS, REASONS FOR CAUTION: This is a retrospective study, which by nature can include selection bias, and the number of cases in the expectant group was <30, which may result in a false-negative result owing to the small sample size. WIDER IMPLICATIONS OF THE FINDINGS: For patients with CIN2/CIN3, the treatment of cervical lesions does not affect the outcome of IVF/ICSI. Patients with CIN2 can enroll for IVF/ICSI cycles, with close follow-up to prevent the progression of cervical lesions, in order to avoid further delay in starting ART. For patients with CIN3, ovulation induction and embryo cryopreservation can be initiated as soon as possible after cervical lesions are treated, and frozen-thawed embryo transfer can be carried out 9-12 months later. STUDY FUNDING/COMPETING INTEREST(S): This work was funded by the Key Clinical Projects of the Peking University Third Hospital (to Y.W., BYSYZD2021014). The authors declare no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Xie W, Wang Y, You K, et al. Impact of cervical intraepithelial neoplasia and treatment on IVF/ICSI outcomes. Hum Reprod. 2023. PMID: 37982414. doi:10.1093/humrep/dead009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。